Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.49 |
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | RGS4 | P49798 | 1/20 | 0.41 |
| ▸ | RGS8 | P57771 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718447 | 0.91 | BRD4 (0.49) | CCR2BRD4F10PLA2G2AMAPT | |
| SCHEMBL4715185 | 0.91 | BRD4 (0.48) | CCR2BRD4ALDH1A1F10ERCC5 | |
| SCHEMBL4715213 | 0.89 | CCR2 (0.51) | CCR2BRD4ALDH1A1F10PLA2G2A | |
| SCHEMBL5119050 | 0.89 | CCR2 (0.62) | CCR2ERCC5MAPTMAPK8MAPK9 | |
| SCHEMBL4711188 | 0.85 | BRD4 (0.53) | CCR2BRD4ALDH1A1ERCC5MAPT | |
| SCHEMBL4712460 | 0.83 | PTGS2 (0.51) | CCR2BRD4ALDH1A1MAPTLMNA | |
| SCHEMBL4712174 | 0.83 | MAPT (0.51) | CCR2BRD4ALDH1A1F10MAPT | |
| SCHEMBL4714910 | 0.82 | CCR2 (0.46) | CCR2BRD4ALDH1A1PLA2G2AERCC5 | |
| SCHEMBL4715116 | 0.81 | CCR2 (0.55) | CCR2BRD4MAPTRGS4RGS8 | |
| SCHEMBL4715522 | 0.80 | RGS4 (0.48) | CCR2BRD4F10PLA2G2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | claimed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | claimed |
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | disclosed |
| EP-1549648-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2008-11-12 | — | — | EP | disclosed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | MAP2K2, MAP2K7, MAP2K3 | CCR2 333/4885BRD4 241/4885ALDH1A1 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.